Exelixis Inc Available-for-sale Securities, Gross Realized Gain (Loss)
Exelixis Inc (EXEL) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $0 for the 12-month period ending 2017-12-29, per its 10-K filed 2018-02-26.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2018-02-26
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-12-29 was $0.00.
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-09-30 was $0.00.
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-06-30 was $0.00.
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-03-31 was $0.00.
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $0.00.
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $0.00.
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $0.00.
- Exelixis Inc available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2017-12-29 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2018-02-26 | $0.00 derived: sum of 2 quarters · filed 2018-02-26 | $0.00 derived: sum of 3 quarters · filed 2018-02-26 | $0.00 10-K · filed 2018-02-26 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 4 quarters · filed 2017-11-01 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-02 | $0.00 10-Q · filed 2017-08-02 | $0.00 derived: sum of 3 quarters · filed 2017-08-02 | $0.00 derived: sum of 4 quarters · filed 2017-11-01 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-01 | $0.00 derived: sum of 2 quarters · filed 2017-05-01 | $0.00 derived: sum of 3 quarters · filed 2017-11-01 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-K · filed 2017-02-27 | |
| 2016-12-30 | $0.00 10-K · filed 2018-02-26 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-01 | |||
| 2016-01-01 | $0.00 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-02-27 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |